CY1121843T1 - Σκευασματα ετανερσεπτης σταθεροποιημενα με ιοντα μαγνησιου - Google Patents
Σκευασματα ετανερσεπτης σταθεροποιημενα με ιοντα μαγνησιουInfo
- Publication number
- CY1121843T1 CY1121843T1 CY20191100709T CY191100709T CY1121843T1 CY 1121843 T1 CY1121843 T1 CY 1121843T1 CY 20191100709 T CY20191100709 T CY 20191100709T CY 191100709 T CY191100709 T CY 191100709T CY 1121843 T1 CY1121843 T1 CY 1121843T1
- Authority
- CY
- Cyprus
- Prior art keywords
- magnesium ion
- ion stabilized
- stabilized receptor
- receptor formulations
- formulations
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 title 1
- 229910001425 magnesium ion Inorganic materials 0.000 title 1
- 108010008165 Etanercept Proteins 0.000 abstract 2
- 229960000403 etanercept Drugs 0.000 abstract 2
- 230000007774 longterm Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Abstract
Η εφεύρεση παρέχει σταθεροποιημένες υδατικές φαρμακευτικές συνθέσεις ετανερσέπτης κατάλληλες για μακροχρόνια αποθήκευση της ετανερσέπτης, μεθόδους παρασκευής αυτών των συνθέσεων, μεθόδους χορήγησης και κιτ που τις περιέχουν.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161548518P | 2011-10-18 | 2011-10-18 | |
US201261669480P | 2012-07-09 | 2012-07-09 | |
PCT/US2012/060739 WO2013059406A1 (en) | 2011-10-18 | 2012-10-18 | Etanercept formulations stabilized with metal ions |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1121843T1 true CY1121843T1 (el) | 2020-07-31 |
Family
ID=48136153
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20191100709T CY1121843T1 (el) | 2011-10-18 | 2019-07-03 | Σκευασματα ετανερσεπτης σταθεροποιημενα με ιοντα μαγνησιου |
Country Status (27)
Country | Link |
---|---|
US (21) | US9302002B2 (el) |
EP (6) | EP2768854A4 (el) |
JP (6) | JP6220789B2 (el) |
KR (7) | KR20140091705A (el) |
CN (6) | CN104010654B (el) |
AR (6) | AR088383A1 (el) |
AU (6) | AU2012326170B2 (el) |
BR (6) | BR112014009022A2 (el) |
CA (6) | CA2851639C (el) |
CY (1) | CY1121843T1 (el) |
DK (1) | DK2768525T3 (el) |
EA (6) | EA027325B1 (el) |
ES (1) | ES2734070T3 (el) |
HK (6) | HK1200719A1 (el) |
HR (1) | HRP20191215T1 (el) |
HU (1) | HUE045624T2 (el) |
IL (6) | IL231827A0 (el) |
IN (3) | IN2014CN02592A (el) |
LT (1) | LT2768525T (el) |
MX (7) | MX367054B (el) |
PL (1) | PL2768525T3 (el) |
PT (1) | PT2768525T (el) |
RS (1) | RS59179B1 (el) |
SG (6) | SG11201401576WA (el) |
SI (1) | SI2768525T1 (el) |
TW (6) | TWI595883B (el) |
WO (6) | WO2013059410A1 (el) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2776657T3 (es) | 2005-06-14 | 2020-07-31 | Amgen Inc | Formulaciones de proteínas autotamponantes |
US10485869B2 (en) | 2011-10-18 | 2019-11-26 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with meglumine |
JP6220789B2 (ja) * | 2011-10-18 | 2017-10-25 | コヒラス・バイオサイエンシズ・インコーポレイテッド | 糖およびポリオールの組合せによって安定化されたエタネルセプト製剤 |
BR112015000203A2 (pt) * | 2012-07-09 | 2017-06-27 | Coherus Biosciences Inc | formulações de etanercept que exibem redução marcada em partículas sub-visíveis |
CN104902914B (zh) * | 2012-09-11 | 2019-01-01 | 科荣生生物科学公司 | 高纯度和优异产量的正确折叠的依那西普 |
RU2663727C2 (ru) * | 2013-05-02 | 2018-08-08 | Мабксьенсе С.А. | Альтернативные составы для химерных полипептидов tnfr:fc |
WO2015056613A1 (ja) * | 2013-10-15 | 2015-04-23 | Meiji Seikaファルマ株式会社 | 安定化されたポリペプチド水性製剤 |
MX2016004605A (es) * | 2013-10-24 | 2016-11-14 | Astrazeneca Ab | Formulaciones de anticuerpos estables acuosas. |
US9700595B2 (en) | 2013-11-29 | 2017-07-11 | Ares Trading Sa | Liquid formulation of a fusion protein comprising TNFR and Fc region |
IS3008B (is) | 2014-05-14 | 2018-12-15 | Calor ehf | Stöðgandi lausnir fyrir prótín og peptíð |
US11357857B2 (en) | 2014-06-20 | 2022-06-14 | Comera Life Sciences, Inc. | Excipient compounds for protein processing |
US10478498B2 (en) | 2014-06-20 | 2019-11-19 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
US20160074515A1 (en) | 2014-06-20 | 2016-03-17 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
US20180200325A1 (en) * | 2014-11-18 | 2018-07-19 | Shionogi & Co., Ltd. | Stabilized peptide composition |
CA2970577A1 (en) * | 2014-12-22 | 2016-06-30 | Ares Trading S.A. | Liquid pharmaceutical composition |
EP3236942A1 (en) * | 2014-12-23 | 2017-11-01 | Drug Discovery Laboratory AS | Protein compositions and use thereof |
IL253218B (en) | 2014-12-31 | 2022-08-01 | Lg Chemical Ltd | A method for preparing a tnfr–fc fusion protein containing a targeted content of unpurified components |
CN104694355B (zh) * | 2015-03-20 | 2016-09-28 | 吉林大学 | 葛根护肝保健酒及其制备方法 |
MX2015010517A (es) * | 2015-08-13 | 2017-02-13 | Landsteiner Scient S A De C V | Composicion de estabilidad mejorada de etanercept. |
JP5938762B1 (ja) * | 2015-09-01 | 2016-06-22 | 日揮株式会社 | マイクロカプセル製剤及びその製造方法 |
CN105748414A (zh) * | 2016-03-02 | 2016-07-13 | 张光泉 | 抗感染米卡芬净冻干组合物及其制备方法 |
JPWO2017179683A1 (ja) * | 2016-04-15 | 2019-02-21 | Meiji Seikaファルマ株式会社 | ミカファンギンの安定化された医薬組成物 |
MX2019004580A (es) * | 2016-10-21 | 2019-08-12 | Amgen Inc | Formulaciones farmaceuticas y metodos para prepararlas. |
WO2018080196A2 (ko) | 2016-10-28 | 2018-05-03 | (주)셀트리온 | 안정한 약제학적 제제 |
MX2017013995A (es) * | 2017-10-31 | 2019-05-01 | Probiomed S A De C V | Formulacion farmaceutica estable de una proteina de fusion. |
CN111110842B (zh) * | 2017-11-30 | 2020-12-11 | 百奥泰生物制药股份有限公司 | 一种治疗il-6相关疾病的人源化抗体的液体制剂 |
KR102494021B1 (ko) * | 2017-12-22 | 2023-02-06 | 삼성바이오에피스 주식회사 | Vegf 길항제를 포함하는 액상 조성물 |
CA3042126A1 (en) | 2018-05-03 | 2019-11-03 | Michael A. Portman | Methods of treating kawasaki disease |
CN111228225B (zh) * | 2018-11-28 | 2022-08-26 | 鲁南制药集团股份有限公司 | 一种重组人肿瘤坏死因子受体-Fc融合蛋白冻干制剂 |
GB201911461D0 (en) | 2019-08-09 | 2019-09-25 | Arecor Ltd | Novel composition |
KR20220122993A (ko) * | 2019-11-26 | 2022-09-05 | 코메라 라이프 사이언시스, 인코포레이티드 | 바이오폴리머 제형을 위한 부형제 화합물 |
IL305010A (en) | 2021-02-17 | 2023-10-01 | Arecor Ltd | An aqueous preparation of a transgenic protein structure that includes an FC domain |
CN114788809B (zh) * | 2022-01-25 | 2023-04-14 | 江苏广承药业有限公司 | 一种氯雷他定液体制剂 |
Family Cites Families (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5605690A (en) | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
IT1240314B (it) | 1989-09-28 | 1993-12-07 | Immunobiology Research Institutes, Inc. | Formulazioni acquose stabilizzate di piccoli peptidi. |
NZ256293A (en) | 1992-09-15 | 1997-06-24 | Immunex Corp | Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist |
US5580856A (en) | 1994-07-15 | 1996-12-03 | Prestrelski; Steven J. | Formulation of a reconstituted protein, and method and kit for the production thereof |
US5656730A (en) | 1995-04-07 | 1997-08-12 | Enzon, Inc. | Stabilized monomeric protein compositions |
EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
US7294481B1 (en) * | 1999-01-05 | 2007-11-13 | Immunex Corporation | Method for producing recombinant proteins |
US6677326B2 (en) * | 1999-03-15 | 2004-01-13 | Arakis, Ltd. | Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration |
WO2000062790A2 (en) | 1999-04-19 | 2000-10-26 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
US20040220103A1 (en) * | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
US20010021380A1 (en) | 1999-04-19 | 2001-09-13 | Pluenneke John D. | Soluble tumor necrosis factor receptor treatment of medical disorders |
BR0108193A (pt) | 2000-02-10 | 2003-02-25 | Wyeth Corp | Processo para tratamento ou inibição de dano celular ou morte celular |
ES2644275T3 (es) | 2000-08-11 | 2017-11-28 | Chugai Seiyaku Kabushiki Kaisha | Preparaciones estabilizadas que contienen anticuerpos |
WO2003102013A2 (en) * | 2001-02-23 | 2003-12-11 | Gonzalez-Villasenor Lucia Iren | Methods and compositions for production of recombinant peptides |
JP4583762B2 (ja) * | 2002-02-27 | 2010-11-17 | イミュネックス・コーポレーション | ポリペプチド製剤 |
BRPI0407649A (pt) | 2003-02-28 | 2006-02-21 | Ares Trading Sa | formulação lìquida de proteìnas de ligação do fator de necrose tumoral, processo de preparação de formulação lìquida de proteìnas de ligação do fator de necrose tumoral e forma de apresentação de formulação |
WO2004082715A1 (ja) | 2003-03-20 | 2004-09-30 | Eisai Co., Ltd. | 炎症性腸疾患治療剤としての併用医薬 |
CN100509847C (zh) | 2003-08-01 | 2009-07-08 | 安美基公司 | 结晶肿瘤坏死因子受体2多肽 |
RS20060259A (en) | 2003-10-14 | 2008-08-07 | Intermune Inc., | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication |
WO2005082377A1 (ja) | 2004-03-01 | 2005-09-09 | Ajinomoto Co., Inc. | 抗ヒトTNF-α抗体活性低下抑制剤 |
US8206981B2 (en) | 2004-03-05 | 2012-06-26 | Dsm Ip Assets B.V. | Process for cell culturing by continuous perfusion and alternating tangential flow |
US20070196364A1 (en) | 2004-07-27 | 2007-08-23 | Human Genome Sciences, Inc. | Pharmaceutical Formulation and Process |
US7597884B2 (en) * | 2004-08-09 | 2009-10-06 | Alios Biopharma, Inc. | Hyperglycosylated polypeptide variants and methods of use |
US7300773B2 (en) | 2004-08-27 | 2007-11-27 | Wyeth Research Ireland Limited | Production of TNFR-Ig |
WO2006122187A2 (en) | 2005-05-10 | 2006-11-16 | Biogen Idec Ma Inc. | Treating and evaluating inflammatory disorders |
JP5068167B2 (ja) | 2005-06-10 | 2012-11-07 | 中外製薬株式会社 | メグルミンを含有するタンパク質製剤の安定化剤、およびその利用 |
ES2776657T3 (es) * | 2005-06-14 | 2020-07-31 | Amgen Inc | Formulaciones de proteínas autotamponantes |
AR058567A1 (es) | 2005-12-20 | 2008-02-13 | Bristol Myers Squibb Co | Formulaciones de proteinas estables |
JP5405122B2 (ja) | 2005-12-21 | 2014-02-05 | ワイス・エルエルシー | 低粘度のタンパク質製剤およびその用途 |
AU2007212147A1 (en) | 2006-02-03 | 2007-08-16 | Medimmune, Llc | Protein formulations |
CA2646508A1 (en) | 2006-03-17 | 2007-09-27 | Biogen Idec Ma Inc. | Stabilized polypeptide compositions |
WO2007107340A2 (en) | 2006-03-21 | 2007-09-27 | Eugen Oetringer | Devices for and methods of analyzing a physiological condition of a physiological subject based on a workload related property |
EP2021030A2 (en) | 2006-04-21 | 2009-02-11 | Amgen, Inc. | Buffering agents for biopharmaceutical formulations |
US20080038753A1 (en) * | 2006-08-01 | 2008-02-14 | Illumigen Biosciences, Inc. | Pharmaceutical manufacturing methods |
EP2081553B1 (en) * | 2006-10-06 | 2020-08-12 | Amgen Inc. | Stable antibody formulations |
EP2094247B1 (en) | 2006-10-20 | 2022-06-29 | Amgen Inc. | Stable polypeptide formulations |
MX2009004519A (es) | 2006-11-03 | 2009-05-12 | Wyeth Corp | Sustancias que inhiben la glucolisis en un cultivo de celulas. |
CA2790018C (en) | 2006-12-21 | 2015-02-03 | Amgen Inc. | Formulations |
KR20090127326A (ko) | 2007-03-02 | 2009-12-10 | 와이어쓰 | 폴리펩티드의 생산을 위한 세포 배양물 중에서 구리 및 글루타메이트의 용도 |
EP2014760A1 (en) | 2007-06-13 | 2009-01-14 | CMC Biopharmaceuticals A/S | A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process |
CN103977404A (zh) * | 2007-06-14 | 2014-08-13 | 比奥根艾迪克Ma公司 | 抗体制剂 |
CA2707483A1 (en) | 2007-11-30 | 2009-06-11 | Wolfgang Fraunhofer | Protein formulations and methods of making same |
MX2010007728A (es) * | 2008-01-15 | 2010-12-21 | Abbott Gmbh & Co Kg | Composiciones proteinicas en polvo y metodos para elaborar las mismas. |
EP2260054B1 (en) | 2008-02-29 | 2015-06-03 | Biogen Idec MA Inc. | Purified immunoglobulin fusion proteins and methods of their purification |
WO2011015926A1 (en) | 2009-08-03 | 2011-02-10 | Avesthagen Limited | A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein |
HUE048980T2 (hu) | 2009-08-11 | 2020-08-28 | Hoffmann La Roche | Fehérjék elõállítása glutaminmentes sejttenyésztõ táptalajban |
EP2490780A4 (en) | 2009-10-20 | 2014-04-09 | Merck Sharp & Dohme | USE OF MIXED MODE CHROMATOGRAPHY FOR CAPTURE AND PURIFICATION OF BASIC ANTIBODY PRODUCTS |
EP2516467A2 (en) | 2009-12-23 | 2012-10-31 | Emergent Product Development Seattle, LLC | Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof |
WO2011134920A1 (en) | 2010-04-26 | 2011-11-03 | Novartis Ag | Improved cell culture medium |
CN102946858B (zh) * | 2010-05-10 | 2015-09-30 | 英塔斯制药有限公司 | 含有免疫球蛋白Fc的多肽的液体制剂 |
US20130209465A1 (en) | 2010-07-30 | 2013-08-15 | Arecor Ltd. | Stabilized Aqueous Antibody Compositions |
WO2012023085A1 (en) | 2010-08-20 | 2012-02-23 | Wyeth Llc | Cell culture of growth factor-free adapted cells |
JP2013536683A (ja) | 2010-08-31 | 2013-09-26 | フリエスランド ブランズ ビー.ブイ. | 真核細胞のための培養培地 |
KR20130142128A (ko) | 2010-10-11 | 2013-12-27 | 애브비 인코포레이티드 | 단백질의 정제 방법 |
JP5996631B2 (ja) * | 2011-04-20 | 2016-09-21 | サンド・アクチエンゲゼルシヤフト | TNFR:Fc融合タンパク質の安定した医薬液剤 |
UY34105A (es) | 2011-06-03 | 2012-07-31 | Lg Life Sciences Ltd | Formulación líquida estable de etanercept |
WO2013003731A2 (en) | 2011-06-29 | 2013-01-03 | Insite Vision Incorporated | Methods of treating recurrent meibomian glands disorder and thereby decreasing the frequency of recurrence |
KR102061355B1 (ko) * | 2011-07-01 | 2019-12-31 | 바이오젠 엠에이 인코포레이티드 | 아르기닌-없는 tnfr : fc-융합 폴리펩티드 조성물 및 이용 방법 |
KR102108663B1 (ko) | 2011-07-01 | 2020-05-07 | 암젠 인크 | 포유동물 세포 배양 |
US9781540B2 (en) * | 2011-07-07 | 2017-10-03 | Qualcomm Incorporated | Application relevance determination based on social context |
DK2729482T3 (en) | 2011-07-08 | 2018-05-07 | Merck Sharp & Dohme | PROCEDURE FOR CLEANING FC-FUSION PROTEIN |
JP6223338B2 (ja) | 2011-08-17 | 2017-11-01 | アレス トレーディング ソシエテ アノニム | 活性型TNFR−Fc融合タンパク質を製造する方法 |
JP6220789B2 (ja) * | 2011-10-18 | 2017-10-25 | コヒラス・バイオサイエンシズ・インコーポレイテッド | 糖およびポリオールの組合せによって安定化されたエタネルセプト製剤 |
CN104902914B (zh) | 2012-09-11 | 2019-01-01 | 科荣生生物科学公司 | 高纯度和优异产量的正确折叠的依那西普 |
-
2012
- 2012-10-18 JP JP2014537223A patent/JP6220789B2/ja active Active
- 2012-10-18 CA CA2851639A patent/CA2851639C/en active Active
- 2012-10-18 EP EP12842226.8A patent/EP2768854A4/en not_active Withdrawn
- 2012-10-18 TW TW101138567A patent/TWI595883B/zh not_active IP Right Cessation
- 2012-10-18 CA CA2851635A patent/CA2851635A1/en not_active Abandoned
- 2012-10-18 BR BR112014009022A patent/BR112014009022A2/pt not_active IP Right Cessation
- 2012-10-18 CA CA2851642A patent/CA2851642A1/en not_active Abandoned
- 2012-10-18 MX MX2014004726A patent/MX367054B/es active IP Right Grant
- 2012-10-18 EA EA201490803A patent/EA027325B1/ru not_active IP Right Cessation
- 2012-10-18 EA EA201490817A patent/EA025663B1/ru unknown
- 2012-10-18 AU AU2012326170A patent/AU2012326170B2/en active Active
- 2012-10-18 AR ARP120103889A patent/AR088383A1/es unknown
- 2012-10-18 JP JP2014537218A patent/JP6104922B2/ja not_active Expired - Fee Related
- 2012-10-18 BR BR112014009087A patent/BR112014009087A2/pt not_active IP Right Cessation
- 2012-10-18 SG SG11201401576WA patent/SG11201401576WA/en unknown
- 2012-10-18 WO PCT/US2012/060745 patent/WO2013059410A1/en active Application Filing
- 2012-10-18 EP EP12842312.6A patent/EP2768535A4/en not_active Withdrawn
- 2012-10-18 IN IN2592CHN2014 patent/IN2014CN02592A/en unknown
- 2012-10-18 WO PCT/US2012/060738 patent/WO2013059405A1/en active Application Filing
- 2012-10-18 PL PL12842352T patent/PL2768525T3/pl unknown
- 2012-10-18 US US13/654,950 patent/US9302002B2/en active Active
- 2012-10-18 US US13/654,919 patent/US9393305B2/en active Active
- 2012-10-18 IN IN2591CHN2014 patent/IN2014CN02591A/en unknown
- 2012-10-18 CN CN201280062747.9A patent/CN104010654B/zh active Active
- 2012-10-18 EA EA201490802A patent/EA028520B1/ru not_active IP Right Cessation
- 2012-10-18 US US13/654,735 patent/US10293049B2/en not_active Expired - Fee Related
- 2012-10-18 TW TW101138566A patent/TWI619504B/zh not_active IP Right Cessation
- 2012-10-18 BR BR112014009031A patent/BR112014009031A2/pt not_active Application Discontinuation
- 2012-10-18 US US13/654,770 patent/US9801942B2/en active Active
- 2012-10-18 EA EA201490801A patent/EA026410B1/ru not_active IP Right Cessation
- 2012-10-18 AR ARP120103886A patent/AR088380A1/es unknown
- 2012-10-18 CN CN201280062748.3A patent/CN104010657A/zh active Pending
- 2012-10-18 CN CN201280062758.7A patent/CN104011073B/zh not_active Expired - Fee Related
- 2012-10-18 EP EP12841522.1A patent/EP2768532A4/en not_active Withdrawn
- 2012-10-18 AR ARP120103884A patent/AR088460A1/es unknown
- 2012-10-18 TW TW101138564A patent/TW201325608A/zh unknown
- 2012-10-18 EA EA201490815A patent/EA025267B1/ru not_active IP Right Cessation
- 2012-10-18 SG SG11201401519RA patent/SG11201401519RA/en unknown
- 2012-10-18 CN CN201280062418.4A patent/CN103998060B/zh not_active Expired - Fee Related
- 2012-10-18 CA CA2851651A patent/CA2851651A1/en not_active Abandoned
- 2012-10-18 RS RSP20190864 patent/RS59179B1/sr unknown
- 2012-10-18 AR ARP120103885A patent/AR088379A1/es unknown
- 2012-10-18 EP EP12841765.6A patent/EP2768533A4/en not_active Withdrawn
- 2012-10-18 BR BR112014009073A patent/BR112014009073A2/pt not_active IP Right Cessation
- 2012-10-18 CA CA2851646A patent/CA2851646A1/en not_active Abandoned
- 2012-10-18 DK DK12842352.2T patent/DK2768525T3/da active
- 2012-10-18 KR KR1020147013301A patent/KR20140091705A/ko not_active Application Discontinuation
- 2012-10-18 EA EA201490804A patent/EA201490804A1/ru unknown
- 2012-10-18 MX MX2014004732A patent/MX2014004732A/es unknown
- 2012-10-18 KR KR1020147013302A patent/KR20140083037A/ko active Search and Examination
- 2012-10-18 SG SG11201401563SA patent/SG11201401563SA/en unknown
- 2012-10-18 MX MX2014004733A patent/MX2014004733A/es unknown
- 2012-10-18 TW TW101138560A patent/TW201325606A/zh unknown
- 2012-10-18 SG SG11201401517VA patent/SG11201401517VA/en unknown
- 2012-10-18 SG SG11201401567YA patent/SG11201401567YA/en unknown
- 2012-10-18 JP JP2014537221A patent/JP6199298B2/ja active Active
- 2012-10-18 AU AU2012326171A patent/AU2012326171B2/en not_active Ceased
- 2012-10-18 ES ES12842352T patent/ES2734070T3/es active Active
- 2012-10-18 AR ARP120103888A patent/AR088382A1/es unknown
- 2012-10-18 CN CN201280062739.4A patent/CN103998061A/zh active Pending
- 2012-10-18 AR ARP120103887A patent/AR088381A1/es unknown
- 2012-10-18 MX MX2014004734A patent/MX2014004734A/es unknown
- 2012-10-18 KR KR1020147013305A patent/KR20140091707A/ko not_active Application Discontinuation
- 2012-10-18 JP JP2014537219A patent/JP6110393B2/ja not_active Expired - Fee Related
- 2012-10-18 AU AU2012326084A patent/AU2012326084B2/en not_active Ceased
- 2012-10-18 BR BR112014009131A patent/BR112014009131A8/pt not_active IP Right Cessation
- 2012-10-18 HU HUE12842352A patent/HUE045624T2/hu unknown
- 2012-10-18 LT LTEP12842352.2T patent/LT2768525T/lt unknown
- 2012-10-18 EP EP12842352.2A patent/EP2768525B1/en active Active
- 2012-10-18 WO PCT/US2012/060741 patent/WO2013059407A1/en active Application Filing
- 2012-10-18 WO PCT/US2012/060743 patent/WO2013059408A1/en active Application Filing
- 2012-10-18 MX MX2014004728A patent/MX2014004728A/es unknown
- 2012-10-18 JP JP2014537222A patent/JP6113176B2/ja not_active Expired - Fee Related
- 2012-10-18 EP EP12841505.6A patent/EP2768531A4/en not_active Withdrawn
- 2012-10-18 AU AU2012326080A patent/AU2012326080B2/en not_active Ceased
- 2012-10-18 PT PT12842352T patent/PT2768525T/pt unknown
- 2012-10-18 TW TW101138561A patent/TW201325607A/zh unknown
- 2012-10-18 SI SI201231635T patent/SI2768525T1/sl unknown
- 2012-10-18 KR KR1020147013303A patent/KR102068462B1/ko active IP Right Grant
- 2012-10-18 AU AU2012326082A patent/AU2012326082B2/en not_active Ceased
- 2012-10-18 TW TW101138565A patent/TWI644681B/zh active
- 2012-10-18 BR BR112014009146A patent/BR112014009146A8/pt not_active IP Right Cessation
- 2012-10-18 JP JP2014537220A patent/JP6220788B2/ja active Active
- 2012-10-18 CN CN201280062761.9A patent/CN104010658A/zh active Pending
- 2012-10-18 WO PCT/US2012/060739 patent/WO2013059406A1/en active Application Filing
- 2012-10-18 CA CA2851628A patent/CA2851628A1/en not_active Abandoned
- 2012-10-18 MX MX2014004725A patent/MX2014004725A/es unknown
- 2012-10-18 WO PCT/US2012/060748 patent/WO2013059412A1/en active Application Filing
- 2012-10-18 AU AU2012326168A patent/AU2012326168B2/en not_active Ceased
- 2012-10-18 KR KR1020147013304A patent/KR20140091706A/ko not_active Application Discontinuation
- 2012-10-18 IN IN2527CHN2014 patent/IN2014CN02527A/en unknown
- 2012-10-18 KR KR1020207000845A patent/KR102163150B1/ko active IP Right Grant
- 2012-10-18 KR KR1020147013306A patent/KR20140079491A/ko active Search and Examination
- 2012-10-18 SG SG11201401562RA patent/SG11201401562RA/en unknown
-
2014
- 2014-03-31 IL IL231827A patent/IL231827A0/en unknown
- 2014-03-31 IL IL231829A patent/IL231829A0/en unknown
- 2014-03-31 IL IL231826A patent/IL231826A0/en unknown
- 2014-03-31 IL IL231824A patent/IL231824A0/en unknown
- 2014-03-31 IL IL231825A patent/IL231825A0/en unknown
- 2014-03-31 IL IL231828A patent/IL231828A0/en unknown
- 2014-04-16 MX MX2019009176A patent/MX2019009176A/es unknown
-
2015
- 2015-02-05 HK HK15101254.2A patent/HK1200719A1/xx unknown
- 2015-02-05 HK HK15101255.1A patent/HK1200851A1/xx not_active IP Right Cessation
- 2015-02-05 HK HK15101256.0A patent/HK1200720A1/xx not_active IP Right Cessation
- 2015-02-05 HK HK15101253.3A patent/HK1200718A1/xx unknown
- 2015-02-05 HK HK15101257.9A patent/HK1200721A1/xx unknown
- 2015-02-05 HK HK15101258.8A patent/HK1200722A1/xx unknown
-
2016
- 2016-03-23 US US15/078,755 patent/US9943601B2/en active Active
- 2016-07-13 US US15/209,484 patent/US9770510B2/en active Active
-
2017
- 2017-09-26 US US15/716,005 patent/US10213508B2/en not_active Expired - Fee Related
- 2017-10-31 US US15/799,798 patent/US11135267B2/en active Active
-
2018
- 2018-03-09 US US15/917,333 patent/US10376588B2/en not_active Expired - Fee Related
-
2019
- 2019-02-25 US US16/284,265 patent/US10772963B2/en active Active
- 2019-03-21 US US16/360,196 patent/US11129876B2/en active Active
- 2019-06-14 US US16/441,088 patent/US20190290765A1/en not_active Abandoned
- 2019-06-14 US US16/441,110 patent/US10987405B2/en active Active
- 2019-06-14 US US16/441,092 patent/US10980884B2/en active Active
- 2019-06-14 US US16/441,095 patent/US10980885B2/en active Active
- 2019-06-14 US US16/441,103 patent/US10888619B2/en active Active
- 2019-06-25 US US16/451,732 patent/US20190328875A1/en not_active Abandoned
- 2019-06-26 US US16/453,154 patent/US20190314499A1/en not_active Abandoned
- 2019-06-26 US US16/453,041 patent/US20190314498A1/en not_active Abandoned
- 2019-06-27 US US16/454,817 patent/US20190314500A1/en not_active Abandoned
- 2019-07-03 CY CY20191100709T patent/CY1121843T1/el unknown
- 2019-07-04 HR HRP20191215TT patent/HRP20191215T1/hr unknown
-
2020
- 2020-09-14 US US17/019,722 patent/US20200405865A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1121843T1 (el) | Σκευασματα ετανερσεπτης σταθεροποιημενα με ιοντα μαγνησιου | |
CY1122786T1 (el) | Δοσολογικα σχηματα για ενωσεις κατηγοριας εχινοκανδινης | |
CY1123407T1 (el) | Σταθερες υδατικες φαρμακοτεχνικες μορφες της αδαλιμουμαμπης | |
CY1119974T1 (el) | Στερεες μορφες 3-(5-αμινο-2-μεθυλ-4-οξο-4η-κιναζολιν-3-υλ)-πιπεριδινο-2,6-διονης και φαρμακευτικες συνθεσεις και χρησεις αυτης | |
CY1122853T1 (el) | Σταθερα σκευασματα λινακλοτιδης | |
CY1123953T1 (el) | Καθυστερημενης απελευθερωσης συνθεσεις λινακλοτιδης | |
BR112015000229A2 (pt) | formulações aquosas estáveis de etanercept | |
EA201690667A1 (ru) | Композиции, содержащие антитело к pdl1 | |
PH12016500739A1 (en) | Inhibitors of the fibrolast growth factor receptor | |
AU2016204248A1 (en) | Boron-Containing Molecules | |
EA201692301A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
EA201390145A1 (ru) | Конъюгаты, частицы, композиции и связанные с ними способы | |
PH12015501609A1 (en) | Phenicol antibacterials | |
EA201591728A1 (ru) | Гетероциклические соединения и способы их применения | |
DOP2015000170A (es) | Compuestos químicos | |
EA201591196A1 (ru) | Композиции и способы для трансдермальной доставки гормонов и других лекарственных средств | |
CY1117210T1 (el) | Παραγωγα 2-οξο-1-ιμιδαζολιδινυλ ιμιδαζοθειαδιαζολης | |
EA201501163A1 (ru) | Модуляторы рецептора cxcr7 | |
EA201600394A1 (ru) | Трициклические соединения пиперидина | |
EA201591717A1 (ru) | Твердые формы гидрохлорида вемурафениба | |
CY1119871T1 (el) | Στερεη μορφη αλατος της aλφa-6-mpeg6-o- υδροξυκωδονης ως αγωνιστες οπιοειδων και χρησεις αυτων | |
CY1118277T1 (el) | Σταθερη φαρμακοτεχνικη μορφη πεξιγανανης | |
CY1121708T1 (el) | Ενωσεις ουριας ινδανυλιου που αναστελλουν την ρ38 map kιναση | |
BR112017004595A2 (pt) | composição farmacêutica contendo inibidor de transportador de fosfato dependente de sódio | |
EA201400444A1 (ru) | Производные 2-оксопиперидинила |